Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CAMP vs SLN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLN Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–1 Matrix Metrics)

SLN Overall Winner 6-Pillar Tally: CAMP 2 – 2 SLN (2 Tie) Matrix Metrics: CAMP 1 – 6 SLN

As of Nov 17, 2026, Silence Therapeutics Plc American Depository Share (SLN) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CAMP carries a Unified Composite Score of 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas SLN carries 45.2/100 (HOLD) at $19.79 (N/M Forward P/E, -10475.6% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAMP vs SLN
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84
SLN NASDAQ Head-to-Head Winner
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.79
-0.05% 1D
Market Cap $1.2B
TTM Revenue $615,000
Forward P/E N/M
Beta / 30D Vol 1.93β · 4% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 25.0 Fund 34.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (18.7% over 20 days), RSI 77
RSI-14: 76.9 · SMA20: $19.76 · SMA50: $14.89

6-Pillar Scorecard Institutional Category Breakdown (CAMP 2 – 2 SLN)

Columns: Metric · CAMP · SLN
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 26.6x N/M
2. Growth & Scale SLN
Revenue Growth (YoY) +138.9% +197.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.3M $615,000
Market Cap $238.5M $1.2B
3. Profitability & Quality SLN
Gross Margin N/A 85.9%
Operating Margin -991.8% -10475.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -146.1% -90.4%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$26M -$64M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Cash $1.32 Book/Sh · -90.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 55.4% (50th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAMP (1) vs SLN (6)
Institutional Metric CAMP SLN Criterion Row Edge
Market Capitalization
Scale
$238.5M $1.2B Larger Scale SLN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+138.9% +197.2% Higher Growth SLN
Operating Margin (TTM)
Profitability
-991.8% -10475.6% Higher Margin CAMP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-146.1% -90.4% Higher ROE SLN
52-Week Range Position
Momentum
22% ($3–$8) 100% ($4–$20) Stronger Trend SLN
Beta / 30D Volatility
Risk Regime
1.34β · 94% Vol 1.93β · 4% Vol Lower Realized Risk SLN
Unified Institutional Score
Composite Signal
43.9 / 100 (HOLD) 45.2 / 100 (HOLD) Higher Composite SLN
Trailing 12M Revenue (USD)
Operating Scale
$5.3M $615,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 85.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$26M ($97M Net Cash) -$64M EBITDA ($1.32 Book/Sh · -90.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +24.73 pp
CAMP: +25.8% · SLN: +1.07%
3M Horizon SLN +60.46 pp
CAMP: -15.05% · SLN: +45.41%
6M Horizon SLN +247.8 pp
CAMP: -4.82% · SLN: +242.98%
1Y Horizon SLN +193.41 pp
CAMP: -3.66% · SLN: +189.75%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAMP vs SLN. Trailing 12-month operating profitability (CAMP -991.8% vs SLN -10475.6%) and valuation multiples (CAMP N/M vs SLN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CAMP ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.3M
Gross MarginN/A
Op. Margin-991.8%
ROE / Fwd P/E-146.1% · N/M
SLN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$615,000
Gross Margin85.9%
Op. Margin-10475.6%
ROE / Fwd P/E-90.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.4%
IV Percentile 50th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SLN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -10475.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAMP vs SLN Key Questions & Quantitative Answers

As of Nov 17, 2026, Silence Therapeutics Plc American Depository Share (SLN) is the stronger overall head-to-head candidate over CAMP4 Therapeutics Corporation (CAMP) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). CAMP carries a Unified Composite Score of 43.9/100 (HOLD) at $3.95 (N/M Forward P/E, -991.8% operating margin), whereas SLN carries 45.2/100 (HOLD) at $19.79 (N/M Forward P/E, -10475.6% operating margin). Technically, CAMP sits in a Neutral phase (RSI 51.9, UNCLASSIFIED options structure) and SLN sits in a Markup phase (RSI 76.9, UNCLASSIFIED options structure).

SLN leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with SLN at +197.2% YoY revenue growth and +0.0% YoY earnings growth on $615,000 TTM revenue (85.9% gross margin, -10475.6% operating margin). On trailing 12-month operating scale, CAMP generates $5.3M in USD-normalized revenue versus $615,000 for SLN. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLN.

CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas SLN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus SLN (-90.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, SLN carries 55.4% implied volatility (50th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.93β · 4% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.